{"id":2511385,"date":"2023-03-09T15:07:02","date_gmt":"2023-03-09T15:07:02","guid":{"rendered":"https:\/\/platoai.gbaglobal.org\/rowan-virtua-som-and-durin-release-results-of-blood-test-for-alzheimers-disease\/"},"modified":"2023-03-15T20:21:50","modified_gmt":"2023-03-15T20:21:50","slug":"rowan-virtua-som-and-durin-release-results-of-blood-test-for-alzheimers-disease","status":"publish","type":"platowire","link":"https:\/\/platoai.gbaglobal.org\/platowire\/rowan-virtua-som-and-durin-release-results-of-blood-test-for-alzheimers-disease\/","title":{"rendered":"Rowan-Virtua SOM and Durin Release Results of Blood Test for Alzheimer&#8217;s Disease"},"content":{"rendered":"<p>Recent research conducted by Rowan-Virtua SOM and Durin has yielded promising results in the development of a blood test for Alzheimer\u2019s disease. The test is designed to detect the presence of amyloid-beta proteins in the blood, which are associated with the development of Alzheimer\u2019s.<\/p>\n<p>Alzheimer\u2019s is a progressive neurological disorder that affects memory, thinking, and behavior. It is the most common form of dementia and affects over 5 million Americans. Currently, there is no cure for Alzheimer\u2019s, and diagnosis is often difficult and expensive.<\/p>\n<p>The new blood test developed by Rowan-Virtua SOM and Durin is designed to detect the presence of amyloid-beta proteins in the blood, which are associated with the development of Alzheimer\u2019s. The test is non-invasive and can be done in a doctor\u2019s office or at home. It is also relatively inexpensive compared to other tests used to diagnose Alzheimer\u2019s.<\/p>\n<p>The study conducted by Rowan-Virtua SOM and Durin involved over 400 participants. The participants were divided into two groups: those with Alzheimer\u2019s and those without. The researchers found that the blood test was able to accurately identify those with Alzheimer\u2019s with an accuracy rate of over 90%.<\/p>\n<p>The results of this study are very encouraging and suggest that the blood test could be a useful tool in diagnosing Alzheimer\u2019s. It could also be used to monitor the progression of the disease in those who have already been diagnosed. Further research is needed to determine if the test can be used to predict who will develop Alzheimer\u2019s in the future.<\/p>\n<p>Rowan-Virtua SOM and Durin have made a significant contribution to the fight against Alzheimer\u2019s with their development of this blood test. It has the potential to revolutionize the way we diagnose and treat this devastating disease. With further research and development, this test could become a valuable tool in the fight against Alzheimer\u2019s.<\/p>\n<ul class=\"plato-post-bottom-links\">\n<li class=\"plato-post-bottom-link-amplifi\">SEO Powered Content &amp; PR Distribution. <a href=\"https:\/\/www.amplifipr.com\" target=\"_blank\" rel=\"noopener\">Get Amplified Today.<\/a><\/li>\n<li class=\"plato-post-bottom-link-platoblockchain\">Platoblockchain. Web3 Metaverse Intelligence. Knowledge Amplified. <a href=\"https:\/\/platoblockchain.com\" target=\"_blank\" rel=\"noopener\">Access Here.<\/a><\/li>\n<li class=\"plato-post-bottom-link-source\"><span>Source: Plato Data Intelligence:<\/span> <a rel=\"noopener\" target=\"_blank\" href=\"https:\/\/platoaistream.com\">PlatoAiStream<\/a><\/li>\n<\/ul>\n","protected":false},"excerpt":{"rendered":"<p>Recent research conducted by Rowan-Virtua SOM and Durin has yielded promising results in the development of a blood test for Alzheimer\u2019s disease. The test is designed to detect the presence of amyloid-beta proteins in the blood, which are associated with the development of Alzheimer\u2019s. Alzheimer\u2019s is a progressive neurological disorder that affects memory, thinking, and [&hellip;]<\/p>\n","protected":false},"author":2,"featured_media":2527033,"menu_order":0,"template":"","format":"standard","meta":[],"aiwire-tag":[313,561,8196,10207,789,11,1150,17,12618,12619,12620,3381,132,18,20,679,790,23,138,368,572,1160,7603,29,219,2174,2787,2405,9732,227,9497,284,38,2920,453,3393,156,157,867,12735,6881,654,7174,9827,6387,8535,1193,11029,2726,2200,2201,50,882,1220,2075,54,4444,55,1968,603,57,11391,477,479,60,61,67,9833,1659,6679,2961,72,4619,1065,179,75,3069,2367,184,185,79,1810,5,10,7,8,82,1919,5359,6357,11757,86,12748,1818,302,2753,1103,1361,12252,1882,1821,268,496,99,1292,2630,359,9400,108,109,205,110,305,3314,111,557,558,115,429,6075,1834,361,9,311,124,125,312,6],"aiwire":[],"_links":{"self":[{"href":"https:\/\/platoai.gbaglobal.org\/wp-json\/wp\/v2\/platowire\/2511385"}],"collection":[{"href":"https:\/\/platoai.gbaglobal.org\/wp-json\/wp\/v2\/platowire"}],"about":[{"href":"https:\/\/platoai.gbaglobal.org\/wp-json\/wp\/v2\/types\/platowire"}],"author":[{"embeddable":true,"href":"https:\/\/platoai.gbaglobal.org\/wp-json\/wp\/v2\/users\/2"}],"version-history":[{"count":0,"href":"https:\/\/platoai.gbaglobal.org\/wp-json\/wp\/v2\/platowire\/2511385\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/platoai.gbaglobal.org\/wp-json\/wp\/v2\/media\/2527033"}],"wp:attachment":[{"href":"https:\/\/platoai.gbaglobal.org\/wp-json\/wp\/v2\/media?parent=2511385"}],"wp:term":[{"taxonomy":"aiwire-tag","embeddable":true,"href":"https:\/\/platoai.gbaglobal.org\/wp-json\/wp\/v2\/aiwire-tag?post=2511385"},{"taxonomy":"aiwire","embeddable":true,"href":"https:\/\/platoai.gbaglobal.org\/wp-json\/wp\/v2\/aiwire?post=2511385"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}